MARKSANS

!Relonchem Limited, a

subsidiary, has received UK marketing authorization for moxonidine tablets in 200 and 400 microgram strengths to treat high blood pressure. This adds to Relonchem's growing UK portfolio, following June's approval for oxybutynin hydrochloride oral solution for overactive bladder. Moxonidine's approval comes despite Marksans' financial weakness in Q1 FY26.